Promising SchistoShield® vaccine moves to human trials in africa
NCT ID NCT05762393
First seen Feb 05, 2026 · Last updated May 20, 2026 · Updated 18 times
Summary
This study tested a new vaccine called SchistoShield® to see if it is safe and triggers an immune response against schistosomiasis, a parasitic disease. Healthy adults aged 20 to 59 in Burkina Faso and Madagascar received three doses of the vaccine or a placebo. The main goal was to check for side effects and how the body reacts to different dose levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHISTOSOMIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Groupe de Recherche Action en Santé (GRAS)
Ouagadougou, Burkina Faso
-
Madagascar Institute for Vaccine Research (University of Antananarivo)
Antananarivo, Madagascar
Conditions
Explore the condition pages connected to this study.